Phase II Trial of Trilaciclib added to Chemotherapy plus Pembrolizumab in the First-line Treatment of patients with Advanced Non-Small Cell Lung Cancer.

  • Enrollment

    This study is not currently enrolling.

  • Associated Conditions

  • Research Area

    Cancer Research

  • Principal Investigator

    George Simon

  • Sponsor

    G1 Therapeutics 1658472